

Atypical Hemolytic Uremic Syndrome Complement
Panel, Serum and Plasma

Patient ID 321	Patient Name IMPLEMENTATION, TEST T	Birth Date 1973-05-01	Sex F	Age 52
Order Number X100513334	Client Order Number X100513334	Ordering Physician TEST	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 05 Nov 2025 06:33		

aHUS Complement Panel, S and P

AHUS Interpretation

SDL

No serologic evidence of complement abnormalities.

Is Eculizumab or Ravulizumab taken?

SDL

Eculizumab

Complement, Total, S

SDL

50 U/mL

Reference Value
≥41

Factor B Complement Antigen, S

1 SDL

28.5 mg/dL

Reference Value
15.2–42.3

Alternative Complement Path Func, S

1 SDL

90 %

Reference Value
≥46

Factor H Complement Antigen, S

1 SDL

20.1 mg/dL

Reference Value
18.5–40.8

Complement C3, S

SDL

100 mg/dL

Reference Value
75–175

CBb Complement, P

2 SDL

0.3 mcg/mL

Reference Value
<1.7

Complement C4, S

SDL

30 mg/dL

Reference Value
14–40

SC5b-9 Complement, P

1 SDL

105 ng/mL

Reference Value
<251

Received: 06 Nov 2025 10:53

Reported: 07 Nov 2025 07:42

Laboratory Notes

- This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
- This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55905	Nikola Baumann Ph.D.	24D1040592

Report Status: Final

Printed 18 Nov 2025

Received and reported dates and times are reported in US Central Time.

Page 1 of 1